US 11,738,078 B2
Severe fever with thrombocytopenia syndrome virus
Yeo-Jeong Choi, Cheongju-si (KR); Su-Jin Park, Cheongju-si (KR); Young-Il Kim, Daejeon (KR); and Min-Ah Yu, Sejong (KR)
Assigned to I.D.BIO., Cheongju-si (KR)
Appl. No. 17/50,602
Filed by I.D.BIO., Cheongju-si (KR)
PCT Filed Apr. 23, 2019, PCT No. PCT/KR2019/004857
§ 371(c)(1), (2) Date Oct. 26, 2020,
PCT Pub. No. WO2019/208995, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 10-2018-0047865 (KR), filed on Apr. 25, 2018.
Prior Publication US 2021/0121557 A1, Apr. 29, 2021
Int. Cl. A61K 39/12 (2006.01); A61P 31/12 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/12 (2018.01); G01N 33/569 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/6056 (2013.01)] 5 Claims
 
1. An immunogenic composition for prevention or treatment of a severe fever with thrombocytopenia syndrome, comprising inactivated severe fever with thrombocytopenia syndrome virus or a gene thereof as an active ingredient, and an adjuvant,
wherein the severe fever with thrombocytopenia syndrome virus or the gene thereof comprises:
(i) a L gene that encodes a protein having the sequence of SEQ ID NO: 17, and a M gene that encodes a protein having the sequence of SEQ ID NO: 18, or
(iii) a L gene that encodes a protein having the sequence of SEQ ID NO: 21, and a M gene that encodes a protein having the sequence of SEQ ID NO: 22.